Implementing a Bayesian approach using Stan with Torsten: Population pharmacokinetics analysis of somatrogonCPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGYIF32024-12-090OAAI
Automated Poisson regression exposure-response analysis for binary outcomes with PoissonERMCPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGYIF32024-07-310OA
Predicting Abrocitinib Efficacy at Week 12 Based on Clinical Response at Week 4: A Post Hoc Analysis of Four Randomized Studies in Moderate-to-Severe Atopic DermatitisDERMATOLOGY AND THERAPYIF4.22024-06-190OAAI
Tumor growth inhibition modeling to support the starting dose for dacomitinibCPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGYIF32022-08-066OA
Population pharmacokinetic-pharmacodynamic modelling of platelet time-courses following administration of abrocitinibBRITISH JOURNAL OF CLINICAL PHARMACOLOGYIF32022-04-118OA
Exposure-response modeling of the effect of glasdegib on cardiac repolarization in patients with cancerEXPERT REVIEW OF CLINICAL PHARMACOLOGYIF32021-05-182OAAI
Pharmacokinetic/Pharmacodynamic Modeling to Support the Re-approval of Gemtuzumab OzogamicinCLINICAL PHARMACOLOGY & THERAPEUTICSIF5.52019-07-0925OAAI
Population pharmacokinetic/pharmacodynamic evaluation of the effect of glasdegib exposure on cardiac repolarization (QT interval) in cancer patientsCANCER RESEARCHIF16.62019-07-012PRE
Improving critical thinking growth for disadvantaged groups within elementary school science: A randomized controlled trial using the Science Writing Heuristic approachscience education and technologyIF3.42018-03-2646PREAI
PharmTeX: a LaTeX-Based Open-Source Platform for Automated Reporting WorkflowAAPS JOURNALIF3.72018-03-163PREAI
Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 studyBLOOD ADVANCESIF7.12017-06-27100OA